Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 171

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

New insights into designing hybrid nanoparticles for lung cancer: Diagnosis and treatment

Mottaghitalab, Fatemeh, Farokhi, Mehdi, Fatahi, Yousef, Atyabi, Fatemeh, Dinarvand, Rassoul · 2019 · Journal of Controlled Release

Abstract

Abstract Lung cancer is the foremost reason of death from cancers with broad genetic and epigenetic diversity. Various strategies are clinically available for diagnosis and treatment of lung cancer. However, in many cases, the disease is diagnosed after malignancy that reduce the survival rate of lung cancer patients due to unsuccessful response to therapy. With the help of nanotechnology, various nanoparticulate systems including organic, inorganic, metallic, and polymeric nanoparticles have been developed for diagnosis and treatment of lung cancer. Each of these nanocarriers possess their own advantages and disadvantages. Combining the organic and inorganic components in a single hybrid nanosystem prepares a new generation of multifunctional nanoparticles with enhanced structural and biological properties. Such nanoparticles not only have beneficial features of all the bulk materials, but also can be tuned in terms of structural and functional moieties to provide carriers with improved diagnostic and therapeutic outcomes. Indeed, hybrid nanoparticles with the ability to incorporate multiple drugs, targeting agents, and photosensitive reagents opened new insights into developing more sensitive and specified systems for diagnosis and treatment of lung cancer compared with conventional nanocarriers. In this review, recent developments in designing different hybrid nanoparticles with diagnostic, therapeutic, and theranostic properties for lung cancer are explained in detail. Graphical abstract Figure. No Caption available.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2019.01.009

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 171

Metadata

Authors
Mottaghitalab, F., Farokhi, M., Fatahi, Y., Atyabi, F., & Dinarvand, R.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2019-02
Volume
295
Pages
250-267
ISSN
0168-3659 (ISSN-L)
OpenAlex
W2911040552
Cited by
171
References
10
FWCI
5.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New insights into designing hybrid nanoparticles for lung cancer: Diagnosis and treatment. https://app.cochat.ai/papers/10.1016/j.jconrel.2019.01.009
The paper
Mottaghitalab, F., Farokhi, M., Fatahi, Y., Atyabi, F., & Dinarvand, R. (2019). New insights into designing hybrid nanoparticles for lung cancer: Diagnosis and treatment. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2019.01.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.